Recent studies have shown that GLP-1 use is associated with a reduction in cases of dementia among people with type 2 diabetes (something that's likely to also be true in a broader population of people at risk for dementia)
Why this matters for India: Generic entry could unlock a 5,000+ crore opportunity over the next 1215 months Prices may drop 3050% initially, and potentially 7075% over time #GLP-1 adoption in diabetes care is expected to rise sharply, adding 0.51% to IPM growth in FY27 Competition is intensifying, with 1015 players vying for share across India, regulated, and emerging markets Novo Nordisk has already launched Ozempic in India (Dec 2025), setting the stage for one of the most closely watched generic transitions in recent pharma history
Always discuss any unusual sensations with your doctor
Under our supervision, your Skinny Shot prescription weight loss treatment plan is designed to be safe, effective, and tailored to your individual needs and goals
Translational Andrology and Urology, 5 (6), 834-843
J Bacteriol